Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 18;6(3):e70075.
doi: 10.1002/jha2.70075. eCollection 2025 Jun.

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials

Ruben A Mesa  1 , Moshe Talpaz  2 , Flora Mazerolle  3 , Boris Gorsh  4 , Manal M'Hari  3 , Antoine Regnault  3 , Catherine Ellis  4 , Zhaohui Wang  4 , Molly Purser  4 , Tom Liu  4 , Bryan Strouse  4 , Dwaipayan Patnaik  4
Affiliations

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials

Ruben A Mesa et al. EJHaem. .

Abstract

Introduction: Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with poorer survival and quality of life.

Methods: Time without transfusion reliance (TWiTR), a method integrating transfusion dependence and survival quality, was applied to three Phase 3 trials of momelotinib in myelofibrosis.

Results: TWiTR demonstrated that patients treated with momelotinib versus comparators spent more time free from transfusions and anemia events.

Conclusion: Momelotinib may lead to improved survival quality for patients with myelofibrosis.

Trial registration: ClinicalTrials.gov identifiers: NCT01969838, NCT02101268, and NCT04173494.

Keywords: JAK inhibitor; momelotinib; myelofibrosis; quality of life; survival; transfusions.

PubMed Disclaimer

Conflict of interest statement

Boris Gorsh, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, and Dwaipayan Patnaik report employment with and stock/stock options in GSK. Boris Gorsh, Molly Purser, Tom Liu, and Dwaipayan Patnaik report support for attending meetings and/or travel from GSK. Flora Mazerolle, Manal M'Hari, and Antoine Regnault report employment with Modus Outcomes, a company of THREAD, which is a consultancy company that received funding to complete projects on behalf of GSK and other pharmaceutical companies. Ruben A. Mesa reports consultancy (honoraria) for Novartis, Sierra Oncology, Genentech, Sierra, Blueprint, Geron, Telios, CTI, Incyte, BMS, AbbVie, GSK, and MorphoSys. Moshe Talpaz reports research funding from BMS and participation on advisory boards for BMS, Kyowa Kirin, and SDP/Sumitomo.

Figures

FIGURE 1
FIGURE 1
TWiTR health status durations in (A) SIMPLIFY‐1, (B) SIMPLIFY‐2, and (C) MOMENTUM. BAT, best available therapy; LFS, leukemia‐free survival; TD, transfusion dependent; TWiTR, time without transfusion reliance.
See this image and copyright information in PMC

References

    1. Vonjo (pacritinib). Prescribing Information, Sobi, 2024, https://www.vonjo.com/sites/default/files/2024‐09/prescribing‐informatio....
    1. Jakafi (ruxolitinib). Prescribing Information, Incyte Corporation, 2023, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202192s028lbl.pdf.
    1. Inrebic (fedratinib). Prescribing Information, Bristol Myers Squibb, 2023, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212327s005lbl.pdf.
    1. Ojjaara (momelotinib). Prescribing Information, GSK, 2024, https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Inform....
    1. Zeidner J. F., Mazerolle F., Norton J., et al., “Time Without Transfusion Reliance: A Novel Patient‐Centric Metric for New Therapies in Myelodysplastic Syndromes,” Haematologica 108, no. 4 (2023): 1196–1199, 10.3324/haematol.2022.281856. - DOI - PMC - PubMed

Associated data

LinkOut - more resources